Bristol Myers Squibb Exceeds First-Quarter Profit Estimates Due to Strong Sales of Eliquis and Cancer Drugs
Bristol Myers Squibb reported first-quarter adjusted earnings of $1.58 per share, surpassing expectations of $1.42, with revenue of $11.49 billion also exceeding forecasts. The performance was driven by strong sales of blood thinner Eliquis and newer cancer drugs, despite declines in older products like Revlimid.
Topics: Drug Sales Earnings Market Performance Pharmaceuticals Profit Revenue